| Trial ID: | L1042 |
| Source ID: | NCT01722513
|
| Associated Drug: |
Alprostadil ﹠Control
|
| Title: |
Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Kidney Diseases|Diabetes Mellitus|Acute Kidney Injury|Kidney Failure, Chronic|Renal Insufficiency
|
| Interventions: |
DRUG: Alprostadil ﹠control
|
| Outcome Measures: |
Primary: Primary Outcome, An absolute increase in SCr \>=0.5mg/dL（\>=44.2μmmol/L）or a \>= 25% increase in SCr from baseline to 72h after the procedure, 72 h | Secondary: Secondary Outcome, The composite of hospitalization for aggravated renal function, acute renal failure, dialysis or hemofiltration, aggravated at least 1 class of heart function, acute left ventricular failure or death from all causes., 30 d
|
| Sponsor/Collaborators: |
Sponsor: Shanghai 10th People's Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
150
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION
|
| Start Date: |
2012-11
|
| Completion Date: |
2014-02
|
| Results First Posted: |
|
| Last Update Posted: |
2012-11-07
|
| Locations: |
Department of Cardiology, Shanghai Tenth People's Hospital, Shanghai, Shanghai, 200072, China
|
| URL: |
https://clinicaltrials.gov/show/NCT01722513
|
